Ferras Alashkar

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Régis Peffault de Latour, Alexander Röth, Austin Kulasekararaj et al. · New England Journal of Medicine · 2024 · 141 citations · Full text

Medicine, Hematology, Pharmacology +7

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

Antonio M. Risitano, Alexander Röth, Juliette Soret et al. · The Lancet Haematology · 2021 · 106 citations

Medicine, Pharmacology, Pharmacotherapy +6

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG

Amin T. Turki, Nikolaos Tsachakis‐Mück, Saskia Leserer et al. · Blood Advances · 2021 · 35 citations · Full text

Life Sciences, Hematology, Immunology +17

Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab

Ferras Alashkar, Colin Vance, Dörte Herich‐Terhürne et al. · Annals of Hematology · 2017 · 32 citations

Life Sciences, Hematology, Immunology +15

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

Andreas Hüttmann, Jan Rekowski, Stefan Müller et al. · Annals of Hematology · 2019 · 27 citations

Medicine, Oncology, Pharmacotherapy +9